The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| TLSI | -2.44% | N/A | N/A | -58% |
| S&P | +14.49% | +91.09% | +13.83% | +75% |
TriSalus Life Sciences, Inc. is an oncology company, which engages in the business of integrating standard-of-care treatments and investigational immunotherapeutic with disruptive pressure enabled drug delivery infusion systems to transform the treatment paradigm for patients battling liver and pancreatic tumors. The firm is also involved in developing an innovative organ-specific platform that prevents optimal delivery and performance of immunotherapeutics in difficult-to-treat diseases. The company is headquartered in Westminster, CO.
No news articles found for TriSalus Life Sciences.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $11.21M | 52.3% |
| Gross Profit | $9.41M | 50.4% |
| Gross Margin | 83.93% | -1.1% |
| Market Cap | $206.97M | 38.1% |
| Market Cap / Employee | $1.88M | 0.0% |
| Employees | 110 | -1.8% |
| Net Income | -$8.29M | -91.3% |
| EBITDA | -$7.17M | 9.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $26.49M | 60.7% |
| Accounts Receivable | $5.57M | 18.4% |
| Inventory | 3.8 | 10.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $33.54M | 49.5% |
| Short Term Debt | $0.12M | -61.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -84.53% | 158.8% |
| Return On Invested Capital | 376.47% | 206.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$7.23M | 46.4% |
| Operating Free Cash Flow | -$7.32M | 45.5% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -5.18 | -7.47 | -6.67 | -5.12 | 20.99% |
| Price to Sales | 4.54 | 4.69 | 4.90 | 4.98 | -6.61% |
| Price to Tangible Book Value | -4.96 | -7.47 | -6.67 | -5.12 | 24.85% |
| Enterprise Value to EBITDA | -15.82 | -20.82 | -25.43 | -26.02 | 48.77% |
| Total Debt | $23.45M | $23.63M | $33.12M | $33.66M | 47.88% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
